Gene testing to predict lung cancer treatment response and monitor recurrence
Part of Cancer, Lungs & breathing clinical trials.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You are diagnosed with non-small cell lung cancer (a common type of lung cancer)
- Your cancer is stage II, III, or IV, meaning it has spread within the lung or to other parts of the body
- You are willing to give blood samples and a tumor tissue sample from a previous biopsy
- You have at least one tumor that can be measured on scans
- You have not received any cancer-fighting drugs before providing your blood sample
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This trial studies a “cell-free DNA” blood test to help diagnose and guide treatment decisions for early non-small cell lung cancer. It may help doctors tailor care based on genetic signals seen in the blood before and around surgery.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study is for people with advanced non-small cell lung cancer whose tumors do not have certain genetic changes (called driver mutations) and whose first treatment did not work well or caused bad side effects within 6 months. The researchers want to use a special test (DNA/RNA-NGS) to look for hidden genetic alterations that might explain why the cancer didn't respond.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.